Disclosure Of Cash Flow Statement [Text Block]

GenSight Biologics S.A. - Filing #2813015

Concept 2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
As at
2020-12-31
Disclosure of cash flow statement [text block]
Description of accounting policy for determining components of cash and cash equivalents [text block]
4
Cash and cash equivalents if different from statement of financial position [abstract]
Cash and cash equivalents
10,610,000 EUR
44,288,000 EUR
37,943,000 EUR
Cash and cash equivalents if different from statement of financial position
10,609,000 EUR
44,288,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.